CollPlant Biotechnologies Ltd. (CLGN)

Market Cap	61.85M
Revenue (ttm)	10.96M
Net Income (ttm)	-7.02M
Shares Out	11.45M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	15.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,622
Open	5.28
Previous Close	5.28
Day's Range	5.25 - 5.44
52-Week Range	4.22 - 8.90
Beta	0.41
Analysts	Strong Buy
Price Target	11.00 (+103.7%)
Earnings Date	Apr 4, 2024

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 75
• Stock Exchange: NASDAQ
• Ticker Symbol: CLGN

Financial Performance

In 2023, CLGN's revenue was $10.96 million, an increase of 3565.22% compared to the previous year's $299,000. Losses were -$7.02 million, -58.53% less than in 2022.

Analyst Forecast

According to one analyst, the rating for CLGN stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(103.70% upside)

Analyst Consensus: Strong Buy